**Core tip:** Although not strictly necessary, there are few studies comparing efficacy and safety of the switch from infliximab original (Remicade^®^) to infliximab biosimilar CT-P13 *vs* the maintenance of the original infliximab. For this reason, we presented a comparative study with the original infliximab. Our observational study demonstrates the real-life clinical results of efficacy and safety of infliximab original and the efficacy and safety after switching from original infliximab to infliximab biosimilar CT-P13 at the 12 mo follow-up. Our results demonstrate there is no statistical difference in remission rate, secondary loss of response or adverse events between both therapies.

INTRODUCTION
============

Inflammatory bowel disease (IBD), which includes Crohn's disease (CD) and ulcerative colitis (UC), is a chronic gastrointestinal disorder of unknown etiology which causes deterioration in the quality of life of the patient\[[@B1]\]. The introduction of biological therapies two decades ago, particularly anti-tumor necrosis factor (TNF)-alpha drugs\[[@B2],[@B3]\], has revolutionized the therapeutic approach of IBD, especially in those patients with severe or refractory disease\[[@B2]\]. Despite the undoubted efficacy of biological therapy, these biological agents are much more expensive than traditional treatments, and so impose a considerable burden on the national healthcare system\[[@B4]\]. However, many biological products have reached or are close to patent expiration. This has led to the development of biosimilar drugs\[[@B5]-[@B7]\].

CT-P13 (Remsima^®^ and Inflectra^®^) was the first biosimilar of infliximab approved by the European Medicines Agency\[[@B8]\] in September 2013 and by the United States Food and Drug Administration (United States FDA)\[[@B9]\] in April 2016 for all indications of the originator product including IBD. The extrapolation of use of biosimilar infliximab was based on two phase III clinical trials in patients with rheumatoid arthritis (RA) (PLANETRA)\[[@B10]\] and ankylosing spondylitis (AS) (PLANETAS)\[[@B11]\]. Both studies at 30 wk proved the similarity of infliximab biosimilar against the reference product (Remicade^®^) in terms of efficacy, safety and immunogenicity. Furthermore, the results of the 102 wk open label extensions of PLANETAS\[[@B11]\] and PLANETRA\[[@B10]\] trials have been recently published, providing important information about the safety, efficacy and immunogenicity of switching from infliximab original to infliximab biosimilar in both AS and RA patients\[[@B12],[@B13]\].

During these years, some observational studies and real-life cohorts have been published on the efficacy and safety of the infliximab biosimilar in IBD\[[@B14]-[@B25]\]. Although not strictly necessary, there are few studies comparing efficacy and safety of the switch from infliximab original (Remicade^®^) to infliximab biosimilar CT-P13 *vs* the maintenance of the infliximab original\[[@B26],[@B27]\]. One of the few studies that provide relevant evidence is the results of the phase IV, double-blind, parallel-group NOR-SWITCH study\[[@B27]\]. This trial proved that switching from infliximab RP to CT-P13 was not inferior to continued treatment with infliximab RP. However, this study has received much criticism because of its methodological limitations and is not powered to perform a subgroup analysis, especially IBD patients\[[@B28]\].

Despite initial concerns about infliximab biosimilar not having enough data about safety, security and immunogenicity, guidance from inflammatory bowel disease societies has gradually moved towards a positive and confident position on CT-P13. The European Crohn's Colitis Organization (ECCO) published its position statement on the use of biosimilars for IBD in December 2016 which states that "when a biosimilar product is registered in the European Union, it is considered to be as efficacious as the reference product when used in accordance with the information provided in the Summary of Product Characteristics"\[[@B29]\].

For all the above, this study is designed to compare the efficacy of infliximab biosimilar CT-P13 against infliximab original, analyzing the loss of response of both at the 12 mo follow-up in patients with IBD.

MATERIALS AND METHODS
=====================

Study design
------------

This was an observational study of two cohorts conducted at the Virgen Macarena Hospital (Seville, Spain). One retrospective cohort that included patients with IBD treated with infliximab original from January 2014 to December 2014, and one prospective cohort with patients who were switching from infliximab original to infliximab biosimilar (CT-P13) from March 2015 to February 2016. We had analyzed the overall efficacy and loss of efficacy in patients in remission at the end of one year after treatment with the original product compared to the results of the year of treatment with infliximab biosimilar. The study was approved by the Research Ethics Committee of the Virgen Macarena Hospital. Good clinical practice guidelines were followed and written informed consent was obtained from all patients.

Patients
--------

In the retrospective cohort we included all the patients with CD or UC who were treated with infliximab original at least once in 2014. In the prospective cohort we included all the patients with CD or UC who had been switching from infliximab original to infliximab biosimilar and had completed a 12 mo follow-up. Montreal classification status was recorded in all patients before enrolment.

Study endpoints and assessments
-------------------------------

The efficacy endpoint was the change in clinical remission in patients with infliximab original, and in patients switched from infliximab RP to CT-P13 assessed at 12 mo.

In patients with CD and UC remission was considered when: (1) Harvey-Bradshaw score (HB) ≤ 4 in patients with CD or partial Mayo score ≤ 2 in patients with UC; (2) C-reactive protein (CRP) ≤ 5 mg/dL; (3) no use of steroids; (4) no surgery related to the disease activity; and (5) no increased dosage at the established follow-up time.

Adverse events (AE) were monitored from the first infusion of CT-P13 until the end of the study and they were recorded according to the Office of Human Research Protection.

Statistical analysis
--------------------

Demographic and nominal results were reported in percentages and frequencies. Numerical results were reported as average and standard deviation in cases of normal distribution and as median and interquartile range (IQR) in cases of asymmetrical distribution. The Wilcoxon test was used to compare the clinical scores (HB Score and partial Mayo Score) and the CRP values of patients. McNemar's test and the Cochran Q test were used to compare both groups' remission. 95% confidence intervals (CIs) were calculated and α was set at 0.05 for the determination of statistical significance. Analysis was performed using SPSS 23 (IBM Corporation).

RESULTS
=======

A total of 98 patients were included in each cohort. 68.4% (*n* = 67) were CD, and 31.6% (*n* = 31) were UC.

Retrospective cohort
--------------------

The median age of patients was 39.9 (standard deviation SD 12.5 years old), (95%CI: 37.4-42.4). Over half of the patient population (55.4%) were men and 70.4% were non-smokers. Median time of the disease before starting the follow-up was 44 \[Interquartile range (IQR) = 18; 100 mo\]. Median duration of ongoing infliximab original treatment at the start of the study was 55 (IQR = 28.7; 72 mo). 40.8% used concomitant thiopurines before starting the follow-up. The baseline demographics and phenotypic characteristics of patients with CD and UC according to the Montreal classiﬁcation are shown in Table [1](#T1){ref-type="table"}.

###### 

Comparative baseline demographics and phenotypic characteristics of patients with Crohn\'s disease and ulcerative colitis in both groups *n* (%)

                                                                              **Prospective cohort**   **95%CI**   **Retrospective cohort**   **95%CI**   ***P* value**
  ----------------------------------- --------------------------------------- ------------------------ ----------- -------------------------- ----------- ---------------
  Characteristics (*n* = 98)                                                                                                                              
  Sex                                 men                                     51 (52)                  41.6-62.4   56 (57.1)                  46.8-67.4   
  women                               47 (48)                                 37.6-58.4                42 (42.9)   32.5-53.2                  0.280       
  Smoking status                      Never                                   67 (68.3)                58.7-78.1   69 (70.4)                  60.9-79.9   
  Previous                            18 (18.4)                               10.2-26.5                16 (16.3)   8.5-24.1                   0.929       
  Current                             13 (13.3)                               6.0-20.5                 13 (13.3)   6.1-20.5                               
  Crohn's disease (*n* = 67)                                                                                                                              
  Age at diagnosis                    A1 (\< 17)                              7 (10.5)                 2.4-18.5    10 (15)                    5.6-24.2    
  A2 (17-40)                          49 (73.1)                               61.8-84.5                48 (71.6)   60.1; 83.2                 0.691       
  A3 ( \> 40)                         11 (16.4)                               6.8-26.0                 9 (13.4)    4.5; 22.3                              
  Location at diagnosis               L1 (ileal)                              18 (26.9)                15.5-38.2   15 (22.4)                  11.7-33.1   
  L2 (colonic)                        26 (38.8)                               26.4-51.2                25 (37.3)   25.0-49.6                  0.887       
  L3 (ileocolonic)                    21 (31.3)                               19.5-43.2                25 (37.3)   25.0-49.6                              
  L4 (upper gastrointestinal tract)   2 (3.0)                                 0.3-10.4                 2 (3.0)     0.4-10.4                               
  Disease behavior                    B1 (non-stricturing, non-penetrating)   38 (56.7)                44.169.3    39 (58.2)                  45.7-70.8   0.860
  B2 (stricturing)                    14 (20.9)                               10.4-31.4                13 (19.4)   9.2-29.6                               
  B3 (penetrating)                    15 (22.4)                               11.7-33.1                15 (22.4)   11.7-33.1                              
  Perianal disease                    Yes                                     37 (55.2)                42.6-67.9   39 (58.2)                  45.7-70.8   0.727
  Extraintestinal manifestations      No                                      42 (62.7)                50.4-75.0   46 (68.7)                  56.8-80.5   0.466
  Ulcerative colitis (*n* = 31)                                                                                                                           
  Extension                                                                                                                                               
  E1 (proctitis)                      13 (41.9)                               22.9-60.9                12 (38.7)   19.9-57.5                              
  E2 (left colitis)                   10 (32.3)                               14,2-50.3                11 (35.5)   17.0-53.9                  0.957       
  E3 (pancolitis)                     8 (25.8)                                8.8-42.9                 8 (25.8)    8.8-42.9                               
  Severity                            S1 (mild)                               11 (35.5)                17.0-53.9   10 (32.3)                  14.2-50.3   
  S2 (moderate)                       16 (51.6)                               32.4-70.8                17 (54.8)   35.7-74.0                  0.962       
  S3 (severe)                         4 (12.9)                                3.6-29.8                 4 (12.9)    3.6-29.8                               
  Extraintestinal manifestations      No                                      26 (83.9)                66.3-94.5   27 (87.1)                  66.3-94.5   0.500
  Prior treatment                                                             75 (76.5)                67.6-85.4   85 (86.7)                  79.5-94     0.097
  Thiopurines                                                                 25 (25.5)                16.4-34.7   25 (25.5)                  16.4-34.7   0.970
  Methotrexate                                                                                                                                            
  Concomitant treatment                                                       50 (51)                  40.6-61.4   40 (40.8)                  30.6-51.1   0.197
  Thiopurines                                                                 8 (8)                    2.2-14.1    7 (7,1)                    1.1-10,1    0.999
  Methotrexate                                                                                                                                            

At the start of the study the global remission was 77.6% (76/98) (95%CI: 68.8-86.3) and 71% (66/93) (95%CI: 61.2-80.7) at the 12 mo follow-up. In total, 76 patients were in remission at the time of switch, 83.7% (62/74) (95%CI: 74.7-92.9) had remained in remission at 12 mo of follow-up.

Five patients discontinued treatment (two endoscopic mucosa healing, three adverse effects including development of cervical neoplasia).

CD
--

In the CD patient group, the median age was 37 (IQR = 30; 47 years). The median time of treatment with infliximab original before starting the follow-up was 59 (IQR = 30; 78 mo). The locations at diagnostic were colonic in 37.3%, with non-stricturing, non-penetrating behavior in 58.2%. 46.3% used concomitant thiopurines before starting the follow-up.

Of the 67 patients analyzed, the basal remission was 76.1% (51/67) (95%CI: 65.2-87.1) and 69.2% (45/65) (95%CI: 57.2-81.2) at the 12 mo follow-up. Of the 51 patients who were in initial remission this was maintained in 82.3% (42/51) (95%CI: 70.9-93.8) of patients at the 12 mo follow-up. Two patients discontinued treatment: Two adverse effects including development of a cervix neoplasia.

The HB score showed significant changes over the 12 mo period \[median HB score 95%CI: 1 (0-2) *vs* 1 (1-3) at month 0 and 12, *P =* 0.005\]. No significant changes were observed in median of CRP levels \[1.0 (0-5) *vs* 0.4 (0.2-2) at 0 and 12 mo, *P =* 0.464\].

Ulcerative colitis
------------------

In the UC patient, the median time of treatment with infliximab original before starting the follow-up was 42 (IQR = 20; 60 mo). The locations at diagnostic were proctitis in 38.7% with a moderate severity in 54.8%.

Of the 31 patients analyzed, the basal remission was 80.6% (25/31) (95%CI: 62.5-92.5), and 75% (21/28) (95%CI: 57.2-92.8) at the 12 mo follow-up. Of the 25 patients who were in initial remission this was maintained in 87% (20/23) (95%CI: 70.9-93.8) of patients at the 12 mo follow-up. Three patients discontinued treatment: (two endoscopic mucosa healing and one adverse effect).

No signiﬁcant changes in the median (95%CI) partial Mayo score were observed in switched patients over the 12 mo \[2 (1-3); *vs* 1 (1-3) at 0; *P =* 0.067\]. No signiﬁcant changes in the median CRP level (95%CI) were observed over the same period \[2 (1-10) *vs* 0.6 (0.2-5.5) at months 0 and 12, *P =* 0.654\].

Prospective cohort
------------------

The median age of patients was 41 (SD 12.7 years). Over half of the patient population (56.1%) were men and 68.3% were non-smokers. Median time of the disease before starting the follow-up was 100 (IQR = 77; 151 mo). Median duration of ongoing infliximab original treatment at the start of the study was 60.7 (IQR = 10.5; 73.5 mo). 51% used concomitant thiopurines before starting the follow-up. The baseline demographics and phenotypic characteristics of patients with CD and UC according to the Montreal classiﬁcation are shown in Table [1](#T1){ref-type="table"}.

Of the 98 patients analyzed, 82.7% (81/98) (95%CI: 74.6-90.7) were in remission at the beginning of the study, and 68.2% (60/88) (95%CI: 57.9-78.5) at the 12 mo follow-up. Of the 81 patients who were in initial remission this was maintained in 72.9% (54/74) (95%CI: 62.2-83.8) of patients at 12 mo.

Ten patients discontinued treatment (3 endoscopic mucosal remission, 6 adverse effects, 1 patient did not attend follow-up visits).

Crohn´s disease
---------------

In the CD patient, median time of treatment with infliximab original before starting the follow-up was 74.3 (IQR = 41; 108 mo). The location at diagnostic was colonic in 38.3%, with non-stricturing, non-penetrating behavior in 56.7%, and 55% had perineal disease. 56.7% used concomitant thiopurines before starting the follow-up.

Of the 67 patients analyzed, the basal remission was 83.6% (56/67) (95%CI: 87.3-93.2) and 67.7% (42/62) (95%CI: 55.3-80.2) at the 12 mo follow-up. Of the 56 patients who were in initial remission this was maintained in 69.8% (37/53) (95%CI: 56.5-83.1) of patients at the 12 mo follow-up (*P =* 0.634). 92.5% (62/67) patients completed the follow-up.

Five patients discontinued treatment: Four adverse effects, one patient did not attend follow-up visits.

The HB score showed significant changes over the 12 mo period \[median HB score 95%CI: 1 (1-2) *vs* 1 (1-3) at months 0 and 12, *P =* 0.007\]. No significant changes were observed in median of CRP levels \[1.0 (0-6) *vs* 0.36 (0.2-2) at 0 and 12 mo (*P =* 0.364)\].

Ulcerative colitis
------------------

In the UC patient, the median time of treatment with infliximab original before starting the follow-up was 52 (IQR = 20; 60 mo). The location at diagnostic was left in 41.9% with a moderate severity in 51.6%.

Of the 31 patients analyzed, the basal remission was 80.6% (25/31) (95%CI: 62.5-92.5), and 69.2% (18/26) (95%CI: 49.6-88.9) at the 12 mo follow-up. Of the 25 patients who were in initial remission this was maintained in 81% (17/21) (95%CI: 62.5.9-92.5) of patients at the 12 mo follow-up. Five patients discontinued treatment: Three endoscopic mucosa healing and two adverse effects.

No signiﬁcant changes in the median (95%CI) partial Mayo score were observed in switched patients over the 12 mo \[2 (1-3) *vs* 1 (0-3) at month 0 and 12, *P =* 0.058\]. No signiﬁcant changes in the median CRP level (95%CI) were observed over the same period \[2 (1-10) *vs* 0.6 (0.2-1.4) at month 0 and 12, *P =* 0.329\].

Comparison analysis
-------------------

The basal remission rate of the infliximab original group was 77.6% *vs* 82.7% of infliximab biosimilar (*P =* 0.474). At 12 mo the remission rate was 71% in infliximab original *vs* 68.2% of biosimilar infliximab (*P =* 0.806) without achieving statistical significance. This is showed in Table [2](#T2){ref-type="table"}.

###### 

Comparison of efficacy and loss of efficacy in both groups

                           **Infliximab original Group**   **95%CI**   **CT-P13 Group**   **95%CI**   ***P* value**   **Rate difference (95%CI)**
  ------------------------ ------------------------------- ----------- ------------------ ----------- --------------- -----------------------------
  Basal global remission   76/98 (77.6%)                   66.8-86.3   81/98 (82.7%)      74.6-90.7   0.474           -0.173-0.071
  Global remission 12 mo   66/93 (71%)                     61.2-80.7   60/88 (68.2%)      51.1-71.4   0.806           -0.117-0.173
  Basal remission CD       51/67 (76.1%)                   65.2-87.1   56/67 (83.6%)      73.9-93.2   0.389           -0.225-0.076
  Remission 12 mo CD       45/65 (69.2%)                   57.2-81.2   42/62 (67.7%)      55.3-80.2   0.992           -0.163-0.192
  Basal UC remission       25/31 (80.6%)                   62.5-92.5   25/31 (80.6%)      62.5-92.5   0.748           -0.29-0.229
  Remission 12 mo UC       21/28 (75%)                     57.2-92.8   18/26 (69.2%)      49.6-88.9   0.866           -0.219-0.334

UC: Ulcerative colitis. CD: Crohn's disease.

The loss of overall efficacy at 12 mo in the infliximab original group was 6.6% and 14.5% in the infliximab biosimilar group, without achieving statistical significance (*P =* 0.835). There were not statistically significant differences observed when comparing the loss of efficacy by type of disease, CD (*P =* 0.992) and UC (*P =* 0.866, Figure [1](#F1){ref-type="fig"}).

![Loss of efficacy at 12 mo in both groups.](WJG-24-5288-g001){#F1}

When we analyzed patients, who were in basal remission, the loss of efficacy was 16.3% in the infliximab original *vs* 27.1% in the infliximab biosimilar at the 12 mo follow-up, without statistical differences (*P =* 0.162). There were also no statistically significant differences when we analyzed by type of disease CD (*P =* 0.205) and UC (*P =* 0.890, Table [3](#T3){ref-type="table"}).

###### 

Comparative of maintenance of remission at 12 mo in patients with initial remission in both groups

                                           **Infliximab original group**   **95%CI**   **CT-P13** **group**   **95%CI**   ***P* value**   **Rate Difference (95%CI)**
  ---------------------------------------- ------------------------------- ----------- ---------------------- ----------- --------------- -----------------------------
  Maintained basal remission at 12 mo      62/74 (83.7%)                   74.7-92.9   54/74 (72.9%)          62.2-83.5   0.162           -0.037-0.253
  Maintained basal remission at 12 mo CD   42/51 (82.3%)                   70.9-93.8   37/53 (69.8%)          56.5-83.1   0.205           -0.056-0.307
  Maintained basal remission at 12 mo UC   20/23 (87%)                     66.4-97.2   17/21 (81.0%)          62.5-92.5   0.890           -0.203-0.23

CD: Crohn\'s disease; UC: Ulcerative colitis.

No signiﬁcant changes in disease activity, measured by HB in CD (*P =* 0.385) and Partial Mayo score in UC (*P =* 0.349) were observed between both groups. Signiﬁcant changes in the median CRP level (95%CI) were observed between both groups (*P =* 0.014), nevertheless, it was always in remission (≤ 5 mg/dL).

Safety
------

Retrospective cohort: 9 AEs occurred in 9/98 (9.2%) patients: One hypertensive crisis, three infusion reactions, one palpitations, one asthenia, one arthralgia, one HBV reactivation, one cervical carcinoma. Four patients discontinued treatment because of AEs. Severe adverse events were considered in a patient with UC for HBV reactivation that needed treatment and one CD patient who developed a cervical carcinoma.

Prospective cohort: 11 AEs occurred in 11/98 (11.2%) patients: One skin reaction, one case of abdominal pain, two cases of headache and two of paresthesia during infusion, one case of Sweet's syndrome, two of polyarthralgia, and two of palpitations. Six patients discontinued treatment because of AEs. Severe adverse event was considered in one patient with CD who had Sweet's syndrome needing hospitalization and discontinued treatment. In addition, one patient with UC discontinued because of paresthesia during the infusion.

There were not statistical differences between each group (*P =* 0.814, 95%CI: 0.115-0.075)

DISCUSSION
==========

Despite initial concerns about infliximab biosimilar, different articles have proved the efficacy and safety of CT-P13. Also, the European Crohn´s Colitis Organization (ECCO) published its favorable position statement on the use of biosimilars for IBD in December 2016\[[@B29]\]. We recently have published three studies in this matter\[[@B15],[@B24]-[@B25]\]. In these studies, we proved the efficacy of CT-P13, although our patients' cohorts (switch cohort) have not been compared to a non-switch cohort. Many studies and practical clinical trials have proved the efficacy of anti-TNF-α in IBD\[[@B2]-[@B4]\]. However, up to 30% of patients show no clinical benefit after induction therapy (primary non-responders), and another 30%-40% lose response during the first year of treatment (secondary non-responders)\[[@B30]\], with an estimated annual risk of loss of efficacy between 13%-15% per patient/year\[[@B31]\]. Consequently, we wanted to explore whether our loss of efficacy in the switch cohort was similar to a non-switch cohort in our centre.

Our observational study proves the real-life clinical results of efficacy and safety of infliximab original and the efficacy and safety after switching from infliximab original to infliximab biosimilar CT-P13 at 12 mo follow-up. Our results prove there is no statistical difference in remission rate, secondary loss of response or adverse events between both therapies. Both groups had similar baseline characteristics. The basal remission in the infliximab original group was 77.6% *vs* 82.7% for infliximab biosimilar. At 12 mo, the infliximab original remission rate was 71% *vs* 68.2% for the infliximab biosimilar group. The loss of overall efficacy at 12 mo in the infliximab original group was 6.6% and 14.5% in the infliximab biosimilar one (*P =* 0.806). The loss of efficacy in patients who were in basal remission was 16.3% in the infliximab original *vs* 27.1% in the infliximab biosimilar. It is important to note that, although the difference in the loss of efficacy between the two groups (10.8%) is high, no statistical differences were observed. We believe that this difference may be caused by the fact that an insufficient number of patients were included in the study and that the intervals of confidence were so high that it was impossible to obtain a statistical difference.

In other hand, nocebo is a concept that should be taken into account in our results. Many patients did not have enough confidence in the biosimilar, and as it has been proved in some studies\[[@B32],[@B33]\], nocebo can play a role in the efficacy of the switch cohort. Another important point to analyze is that, although present in both groups, the CD patients' median of HB score showed significant changes over the 12 mo, but it never went over the definition of remission (≤ 4). In both groups, in UC patients the median partial Mayo score remained without changes, CRP levels remained without clinically relevant changes in both groups (≤ 5). We did not find changes in the clinical and analytical parameters, and so we believe that the strong nocebo effect in the biosimilar group explains this loss of efficacy.

In the NOR-SWITCH trial\[[@B27]\] the proportion of patients with disease worsening after six months of stable disease was 26.2% in the infliximab original arm and 29.6% in the CT-P13 arm, after 52 wk. The worsening of the disease happened more frequently in CD patients, however the authors concluded that switching from infliximab original to infliximab biosimilar (CT-P13) was not inferior to continued treatment with infliximab original regarding efficacy, safety and immunogenicity. Also, in the 26 wk open label NOR-SWITCH EXTENSION trial reported in the ECCO congress last February\[[@B34]\], safety and immunogenicity were assessed regarding CT-P13 treatment throughout the 78 wk study period (maintenance group) compared to switching from infliximab original to CT-P13 at week 52 (switch group). Overall disease worsening occurred in 16.8% of patients in the maintenance group and in 11.6% in the switch group. In CD, disease worsening occurred in 20.6% and 13.1% and in UC in 15.4% and 2.9% of patients in the maintenance and switch group, respectively. These results were within the non-inferiority margin (15%).

These results are similar in other studies. In the SECURE study\[[@B35]\] infliximab serum concentrations in adults with ulcerative colitis (*n* = 59) and Crohn's disease (*n* = 61) were examined 16 wk after switching from infliximab original to CT-P13. Serum infliximab concentration with CT-P13 was not inferior to those with infliximab original. Furthermore, no significant changes were noted in clinical and biochemical variables, quality of life and tolerability\[[@B35]\]. In the PROSIT-BIO study\[[@B36]\] the efficacy estimations were 95.7%, 86.4%, and 73.7% for naive; 97.2%, 85.2%, and 62.2% for pre-exposed; and 94.5%, 90.8%, and 78.9% for switch at 8 wk, 16 wk, and 24 wk respectively. 12.1% of adverse events were reported, 38 (6.9%) of them being infusion-related reactions. In a prospective observational single center study\[[@B26]\], that included 191 patients who were switched from original infliximab to CT-P13 and 19 patients who continued with the original. They showed no statistical difference in remission (58.1% *vs* 47.4%, *P =* 0.37), response (12.6% *vs* 10.5%, *P =* 0.80), secondary loss of response (24.6% *vs* 42.1%, *P =* 0.10), or adverse events (4.7% *vs* 0, *P =* 1.0) between those who switched to CT-P13 and those who continued infliximab original at the 12 mo follow-up\[[@B26]\].

All data is in accordance with our results. All observational post-marketing studies published to date have reported positive outcomes for efficacy measures in patients with CD and UC treated with CT-P13, irrespective of prior anti-TNF-α treatment\[[@B14]-[@B26]\]

Finally, the recently published systematic review with meta-analysis\[[@B37]\], in patients with CD switching from infliximab RP to CT-P13 demonstrated high rates of sustained clinical response at 30-32 wk (0.85, 95%CI: 0.71-0.93) and 48-63 wk (0.75, 95%CI: 0.44-0.92) and high rates for sustained clinical remission 0.74 (95%CI: 0.55-0.87) and 0.92 (95%CI: 0.38-0.99), at 16 wk and 51 wk respectively.

In our study, 9.2% (9/98) of patients had drug-related adverse events with infliximab original, four patients discontinued the treatments for this reason. In the infliximab biosimilar 11.2% (11/98) of patients had drug-related adverse events, six patients discontinued treatment because of AEs. These data are related to the results of several studies on the rate of adverse events between 10%-20%.

Our study has some limitations. First of all, and perhaps most importantly, we analyzed a retrospective cohort of patients with infliximab original, which could be a methodological deficit with an error of data interpretation. Similarly, we could not measure calprotectine, drug trough levels, or the presence of antidrug antibodies as has been done in other studies, because at the time of the study these were not available in our hospital. Therefore, it has not been possible to ascertain the cause of the loss of response observed in some patients. We were also unable to measure mucosal healing or perform an endoscopy on any of the patients at the time of the study.

Despite the limitations in our study, we believe that it shows real data in clinical practice in the one-year follow-up. The loss of efficacy in patients in clinical remission treated with biosimilars was 10.8%, close to the margin of non-inferiority of 15% as other previously published studies\[[@B25]-[@B32]\]. We conclude that the overall efficacy and loss of treatment response with Infliximab biosimilar (CT-P13) is similar to that observed with Infliximab original in patients who were switching at the 12 mo follow-up.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Infliximab was the first monoclonal antibody against tumor necrosis factor alpha approved by the US Food and Drug Administration (United States FDA) and European Medicines Agency (EMA) in the treatment of inflammatory bowel disease (IBD). Despite the undoubted efficacy of this biological therapy, this biological agent is much more expensive than traditional treatments and, therefore, imposes a considerable burden on the national health system. However, with the recent expiration of its patent, biosimilar medicines have been developed. CT-P13 (Remsima^®^ and Inflectra^®^) was the first biosimilar of infliximab approved by EMA and United States FDA for all indications of the originator product including IBD. The effectiveness in IBD is being debated due to the approval of this biosimilar was based on clinical trials in rheumatological diseases.

Research motivation
-------------------

Some observational studies and real-life cohorts have been published on the efficacy and safety of the infliximab biosimilar in naive patients with IBD. Although not strictly necessary, there are few studies comparing efficacy and safety of the switch from infliximab original to infliximab biosimilar CT-P13 *vs* the maintenance of the infliximab original.

Research objectives
-------------------

To compare the efficacy of infliximab biosimilar, against infliximab original, analyzing the loss of response of both at the 12 mo follow-up in patients with IBD

Research methods
----------------

An observational study of two cohorts has been conducted. One retrospective cohort that included patients with IBD treated with Infliximab original, and a prospective cohort of patients who were switching from infliximab original to infliximab biosimilar. 98 patients were included in each cohort. We had analyzed the overall efficacy and loss of efficacy in patients in remission at the end of one year after treatment with the original drug compared to the results of the year of treatment with the biosimilar. The efficacy was reported based clinical scores \[Harvey-Bradshaw score (HB) ≤ 4 in patients with Crohn's disease (CD) or partial Mayo score ≤ 2 in patients with ulcerative colitis (UC)\] and biochemical test. Wilcoxon test, McNemar´s test and the Cochran *Q* test were used to compare the variables in both periods.

Research results
----------------

This study demonstrated the overall efficacy and the loss of overall efficacy for infliximab original and infliximab biosimilar were similar per year of treatment.

The loss of efficacy in patients who were in basal remission was 16.3% in the infliximab original *vs* 27.1% in the infliximab biosimilar. This 10.8% of difference in the loss of efficacy between the two groups did not show a statistical difference. No signiﬁcant changes in disease activity, measured by HB in CD (*P =* 0.385) and Partial Mayo score in UC (*P =* 0.349) were observed between both groups. Signiﬁcant changes in the median CRP level (95%CI) were observed between both groups (*P =* 0.014), nevertheless, it was always in remission (≤ 5 mg/dL). Adverse events were similar in both cohorts.

Research conclusions
--------------------

Our study suggests that the overall efficacy and loss of treatment response with infliximab biosimilar (CT-P13) is similar to that observed with infliximab original in patients who were switching at the 12 mo follow-up. The high difference in the loss of efficacy shown in patients who were in basal remission with infliximab original *vs* infliximab biosimilar could be explained by the following: in our data we found the intervals of confidence in both groups were so high that it was impossible to obtain a statistical difference, and in other hand, nocebo is a concept that should be taken into account in our results. Many patients did not have enough confidence in the biosimilar the first year.

Research perspectives
---------------------

Future prospective comparative studies with long-term follow-up are necessary to discriminate the loss of efficacy in patient who were switched to infliximab biosimilar.
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